Editorial: Colorectal cancer and statins: reflections from the end of the road.
Statins are among the most widely prescribed drugs in the United States. In addition to their established lipid-lowering and cardiovascular protective effect, some case-control studies have suggested that statins could have chemopreventive effects for colorectal cancer (CRC). In this issue of the Journal, Singh et al. examined this question using a potentially powerful population-based "electronic cohort" design, which essentially eliminates many of the biases inherent in case-control and traditional cohort studies. They found no evidence of a chemoprotective effect of statin use, a finding that is consistent with previous cohort and interventional studies that have addressed this issue. We conclude that the best-designed studies of the issue indicate that statin use is neither a major risk factor nor a protective factor for CRC and that we have come very near to the end of the road for the hypothesis relating statins to CRC risk.
Ahnen
Dennis J
DJ
Byers
Tim
T
D000368:Aged; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D008350:Manitoba / Q000453:epidemiology; D008875:Middle Aged; D012042:Registries; D012107:Research Design; D012923:Social Class
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors